Flotufolastat F-18: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Flotufolastat F-18. Educational only — not medical advice.
Labeled uses
POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Source: FDA labeling via NIH DailyMed (set 907ac4a4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.